Prevention and management of chronic heart failure in patients at risk

American Journal of Cardiology

Volumn 91, Issue 9 SUPPL. 1, 2003, Pages 10-17

  Dei Cas, Livio ^b   Metra, Marco ^a   Nodari, Savina ^b   Dei Cas, Alessandra ^b   Gheorghiade, Mihai ^b  

^a SPEDALI CIVILI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOSYLATED HEMOGLOBIN; RAMIPRIL; STATIN; WARFARIN;

CARDIOVASCULAR RISK; CHRONIC DISEASE; COMORBIDITY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE COURSE; EPIDEMIC; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SYMPTOM; TREATMENT PLANNING; UNITED STATES;

EID: 0038404900     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03369-6     Document Type: Conference Paper

References (70)

1. Packer M., Cohn J.N. Consensus recommendations for the management of chronic heart failure. II. Management of heart failure approaches to the prevention of heart failure . Am J Cardiol. 83:(suppl):1999;9A-38A.
2. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldmanmd A.M., Francis G.S., Ganiats T.G., Goldstein S., Gregoratos G., Jessup M.L., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Circulation. 104:2001;2996-3007.
3. Smith E.S. III, Trussell S., Mencer L.J. Prevention of heart failure. Curr Opin Cardiol. 17:2002;512-517.
4. Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 22:2001;1527-1560.
5. Bristow M.R. Management of heart failure. Braunwald E., Zipes D.P., Libby P. Heart Disease: A Textbook of Cardiovascular Medicine. 2001;635-651 WB Saunders, Philadelphia.
6. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure the Framingham Study . J Am Coll Cardiol. 22:(suppl A):1993;6A-13A.
7. Kannel W.B., D'Agostino R.B., Silbershatz H., Belanger A.J., Wilson P.W., Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 159:1999;1197-1204.
8. He J., Ogden L.G., Bazzano L.A., Vupputuri S., Loria C., Whelton P.K. Risk factors for congestive heart failure in US men and women NHANES I epidemiologic follow-up study . Arch Intern Med. 161:2001;996-1002.
9. Fox K.F., Cowie M.R., Wood D.A., Coats A.J., Gibbs J.S., Underwood S.R., Turner R.M., Poole-Wilson P.A., Davies S.W., Sutton G.C. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 22:2001;228-236.
10. Levy D., Larson M.G., Vasan R.S., Kannel W.B., Ho K.K. The progression from hypertension to congestive heart failure. JAMA. 275:1996;1557-1562.
11. Richards A.M., Nicholls M.G., Troughton R.W., Lainchbury J.G., Elliott J., Frampton C., Espiner E.A., Crozier I.G., Yandle T.G., Turner J. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol. 39:2002;1182-1188.
12. Vaccarino V., Holford T.R., Krumholz H.M. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol. 36:2000;130-138.
13. Strauer B.E. Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure. Am J Cardiol. 65:(suppl):1990;34G-41G.
14. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1990;1561-1566.
15. Aronow W.S., Ahn C., Kronzon I., Koenigsberg M. Congestive heart failure, coronary events and atherothrombotic brain infarction in elderly blacks and whites with systemic hypertension and with and without echocardiographic and electrocardiographic evidence of left ventricular hypertrophy. Am J Cardiol. 67:1991;295-299.
16. Quinones M.A., Greenberg B.H., Kopelen H.A., Koilpillai C., Limacher M.C., Shindler D.M., Shelton B.J., Weiner D.H. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials significance of left ventricular hypertrophy . J Am Coll Cardiol. 35:2000;1237-1244.
17. Mathew J., Sleight P., Lonn E., Johnstone D., Pogue J., Yi Q., Bosch J., Sussex B., Probstfield J., Yusuf S. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 104:2001;1615-1621.
18. Psaty B.M., Smith N.L., Siscovick D.S., Koepsell T.D., Weiss N.S., Heckbert S.R., Lemaitre R.N., Wagner E.H., Furberg C.D. Health outcomes associated with antihypertensive therapies used as first-line agents a systematic review and meta-analysis . JAMA. 277:1997;739-745.
19. Vaccarino V., Berger A.K., Abramson J., Black H.R., Setaro J.F., Davey J.A., Krumholz H.M. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol. 88:2001;980-986.
20. Levy D., Kenchaiah S., Larson M.G., Benjamin E.J., Kupka M.J., Ho K.K., Murabito J.M., Vasan R.S. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 347:2002;1397-1402.
21. Pearson T.A., Blair S.N., Daniels S.R., Eckel R.H., Fair J.M., Fortmann S.P., Franklin B.A., Goldstein L.B., Greenland P., Grundy S.M., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke 2002 update: Consensus Panel Guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases . Circulation. 106:2002;388-391.
22. Joint British recommendations on prevention of coronary heart disease in clinical practice summary . BMJ. 320:2000;705-708.
23. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Collaborative Research Group . JAMA. 283:2000;1967-1975.
24. Hansson L., Lindholm L.H., Ekbom T., Dahlof B., Lanke J., Schersten B., Wester P.O., Hedner T., de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study . Lancet. 354:1999;1751-1756.
25. Pahor M., Psaty B.M., Alderman M.H., Applegate W.B., Williamson J.D., Cavazzini C., Furberg C.D. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies a meta-analysis of randomised controlled trials . Lancet. 356:2000;1949-1954.
26. Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugsresults of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration . Lancet. 356:2000;1955-1964.
27. Solang L., Malmberg K., Ryden L. Diabetes mellitus and congestive heart failure further knowledge needed . Eur Heart J. 20:1999;789-795.
28. Suskin N., McKelvie R.S., Burns R.J., Latini R., Pericak D., Probstfield J., Rouleau J.L., Sigouin C., Solymoss C.B., Tsuyuki R., White M., Yusuf S. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J. 21:2000;1368-1375.
29. Reis S.E., Holubkov R., Edmundowicz D., McNamara D.M., Zell K.A., Detre K.M., Feldman A.M. Treatment of patients admitted to the hospital with congestive heart failure specialty-related disparities in practice patterns and outcomes . J Am Coll Cardiol. 30:1997;733-738.
30. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease the Framingham study . JAMA. 241:1979;2035-2038.
31. Iribarren C., Karter A.J., Go A.S., Ferrara A., Liu J.Y., Sidney S., Selby J.V. Glycemic control and heart failure among adult patients with diabetes. Circulation. 103:2001;2668-2673.
32. Shindler D.M., Kostis J.B., Yusuf S., Quinones M.A., Pitt B., Stewart D., Pinkett T., Ghali J.K., Wilson A.C. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 77:1996;1017-1020.
33. Dries D.L., Sweitzer N.K., Drazner M.H., Stevenson L.W., Gersh B.J. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 38:2001;421-428.
34. Stone P.H., Muller J.E., Hartwell T., York B.J., Rutherford J.D., Parker C.B., Turi Z.G., Strauss H.W., Willerson J.T., Robertson T., et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis: the MILIS Study Group . J Am Coll Cardiol. 14:1989;49-57.
35. Malmberg K., Yusuf S., Gerstein H.C., Brown J., Zhao F., Hunt D., Piegas L., Calvin J., Keltai M., Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry . Circulation. 102:2000;1014-1019.
36. Taegtmeyer H., McNulty P., Young M.E. Adaptation and maladaptation of the heart in diabetes part I: general concepts . Circulation. 105:2002;1727-1733.
37. Dei Cas L., Buia E., Manca C., Metra M., Pelagatti T. Il cuore nel diabetico. Recenti Prog Med. 74:1983;53-64.
38. Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Lee E.T., Welty T.K., Fabsitz R.R., Robbins D., Rhoades E.R., Howard B.V. Impact of diabetes on cardiac structure and function the Strong Heart Study . Circulation. 101:2000;2271-2276.
39. Mizushige K., Yao L., Noma T., Kiyomoto H., Yu Y., Hosomi N., Ohmori K., Matsuo H. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 101:2000;899-907.
40. Nichols G.A., Hillier T.A., Erbey J.R., Brown J.B. Congestive heart failure in type 2 diabetes prevalence, incidence, and risk factors . Diabetes Care. 24:2001;1614-1619.
41. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes UKPDS 38 . BMJ. 317:1998;703-713.
42. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients the Heart Outcomes Prevention Evaluation Study Investigators . N Engl J Med. 342:2000;145-153.
43. Dagenais G.R., Yusuf S., Bourassa M.G., Yi Q., Bosch J., Lonn E.M., Kouz S., Grover J. Effects of ramipril on coronary events in high-risk persons results of the Heart Outcomes Prevention Evaluation Study . Circulation. 104:2001;522-526.
44. Gheorghiade M., Bonow R.O. Chronic heart failure in the United States a manifestation of coronary artery disease . Circulation. 97:1998;282-289.
45. Franciosa J.A., Wilen M., Ziesche S., Cohn J.N. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 51:1983;831-836.
46. Bart B.A., Shaw L.K., McCants C.B. Jr, Fortin D.F., Lee K.L., Califf R.M., O'Connor C.M. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 30:1997;1002-1008.
47. Yusuf S., Pepine C.J., Garces C., Pouleur H., Salem D., Kostis J., Benedict C., Rousseau M., Bourassa M., Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 340:1992;1173-1178.
48. Bristow M.R. β-Adrenergic receptor blockade in chronic heart failure. Circulation. 101:2000;558-569.
49. Gheorghiade M., Bonow R.O. Introduction and overview beta-blocker therapy in the management of chronic heart failure . Am J Med. 110:(suppl 7A):2001;1S-5S.
50. Metra M., Nardi M., Giubbini R., Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 24:1994;1678-1687.
51. Metra M., Giubbini R., Nodari S., Boldi E., Modena M.G., Dei Cas L. Differential effects of beta-blockers in patients with heart failure a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol . Circulation. 102:2000;546-551.
52. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J 2003;145:292-299.
53. Lindenfeld J., Robertson A.D., Lowes B.D., Bristow M.R. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol. 38:2001;1950-1956.
54. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999;353:9-13.
55. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
56. Wallhaus T.R., Taylor M., DeGrado T.R., Russell D.C., Stanko P., Nickles R.J., Stone C.K. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 103:2001;2441-2446.
57. Cleland J.G., Alamgir F., Nikitin N.P., Clark A.L., Norell M. What is the optimal medical management of ischemic heart failure? Prog Cardiovasc Dis. 43:2001;433-455.
58. Rutherford J.D., Pfeffer M.A., Moye L.A., Davis B.R., Flaker G.C., Kowey P.R., Lamas G.A., Miller H.S., Packer M., Rouleau J.L., et al. Effects of captopril on ischemic events after myocardial infarction results of the Survival and Ventricular Enlargement trial. SAVE Investigators . Circulation. 90:1994;1731-1738.
59. A randomized controlled trial of aspirin in persons recovered from a myocardial infarction. JAMA. 243:1980;661-668.
60. Klimt C.R., Knatterud G.L., Stamler J., Meier P. Persantine-Aspirine Reinfarction Study. Part II. Secondary coronary prevention with aspirin and persantine. J Am Coll Cardiol. 7:1986;251-269.
61. Teo K.K., Yusuf S., Pfeffer M., Torp-Pedersen C., Kober L., Hall A., Pogue J., Latini R., Collins R. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin a systematic review . Lancet. 360:2002;1037-1043.
62. The WASH study (Warfarin/Aspirin Study in Heart failure) rationale, design and end-points: the WASH study Steering Committee and Investigators. Eur J Heart Fail. 1:1999;95-99.
63. Bonow R.O. Myocardial viability and prognosis in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 39:2002;1159-1162.
64. Krum H., McMurray J.J. Statins and chronic heart failure do we need a large-scale outcome trial? J Am Coll Cardiol. 39:2002;1567-1573.
65. Vredevoe D.L., Woo M.A., Doering L.V., Brecht M.L., Hamilton M.A., Fonarow G.C. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 82:1998;323-328.
66. Maggioni P.A. Debate should statin be used in patients with heart failure? Curr Control Trials Cardiovasc Med. 2:2001;266-267.
67. Rauchhaus M., Coats A.J., Anker S.D. The endotoxin-lipoprotein hypothesis. Lancet. 356:2000;930-933.
68. Kjekshus J. Debate statins should be used in patients with heart failure . Curr Control Trials Cardiovasc Med. 2:2001;268-270.
69. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 3:1997;249-254.
70. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., Kannel W.B., Vasan R.S. Obesity and the risk of heart failure. N Engl J Med. 347:2002;305-313.